Meriden, Connecticut is home to one of the world’s most prolific vaccine and protein developers. Protein Sciences Corp. is producing one of the first doses of its FDA approved Flublok influenza vaccine to the public this season. The vaccine gained headlines for its genetically modified baculovirus that is reproduced inside insect cells, reducing the production time to six to eight weeks.
Founded in 1983, Protein Sciences has been developing vaccines and biopharmaceuticals for 30 years, relying on its proprietary BEVS protein expression technology. The company also partners with other organizations to develop and manufacture a variety of therapeutics and gene therapies.
In January of 2013, the U.S. Food and Drug Administration approved the sale of Flublok to people ages 18 to 49. Protein Sciences hopes to eventually garner approval for patients over the age of 50. This flu season, the company is shipping 250,000 doses of the vaccine, a venture that will produce millions of dollars in revenue.
Flublok is produced without the use of chicken eggs, antibiotics, live viruses, formaldehyde or preservatives. It is also free of thimerosal, a derivative of mercury, and latex found in other vaccines. While other vaccine production processes date back to the 1950s, Protein Sciences using 21st century technology to make more effective, faster and safer vaccines.
Nevertheless, Protein Sciences is not just about making money. The company’s mission is to save lives and improve people’s health through its research and development of medicine and therapies. It places significant importance on values like integrity, respect, and excellence.
We are proud to assist them with this mission, supporting their Microsoft Dynamics GP system.
Source: Hartford County Business Journal – Protein Sciences flu vaccine on the way
If you are a manufacturing company that is interested in Microsoft Dynamics GP call CAL Business Solutions, 860-485-0910x 4 or email@example.com
By CAL Business Solutions, www.calszone.com